Introduction
Materials and methods
Ethics approval
Tissue samples collection
Immunohistochemical staining
Cell culture
RNA interference and cell transfection
RNA extraction and qRT-PCR
Western blot analysis
Co-immunoprecipitation (Co-IP) assay
Celigo cell counting assay
Colony formation assay
Cell apoptosis detection
Transwell assay
Wound-healing assay
Sphere-forming assay
Xenograft tumor assay
Microarray analysis
Statistical analysis
Results
PHF5A is abundantly expressed in GC
PHF5A expression | Tumor tissue | Normal tissue | P value | ||
---|---|---|---|---|---|
Cases | Percentage | Cases | Percentage | ||
Low | 55 | 48.8% | 103 | 92.0% | < 0.0001 |
High | 59 | 51.2% | 9 | 8.0% |
Correlation between the expression level of PHF5A and the pathological characteristics of GC
Features | No. of patients | PHF5A expression | P value | |
---|---|---|---|---|
Low | High | |||
All patients | 114 | 55 | 59 | |
Age (years) | 0.260 | |||
≤ 64 | 58 | 31 | 27 | |
> 64 | 56 | 24 | 32 | |
Gender | 0.048 | |||
Male | 79 | 43 | 36 | |
Female | 35 | 12 | 23 | |
Tumor size | 0.889 | |||
< 5 cm | 48 | 23 | 25 | |
≥ 5 cm | 58 | 27 | 31 | |
Differentiation | 0.814 | |||
Low | 41 | 19 | 22 | |
Mediate | 57 | 29 | 28 | |
High | 3 | 1 | 2 | |
T Infiltrate | 0.047 | |||
T1 | 6 | 4 | 2 | |
T2 | 12 | 8 | 4 | |
T3 | 73 | 35 | 38 | |
T4 | 23 | 8 | 15 | |
lymphatic metastasis (N) | 0.182 | |||
N0 | 18 | 10 | 8 | |
N1 | 16 | 10 | 6 | |
N2 | 26 | 12 | 14 | |
N3 | 54 | 23 | 31 | |
Stage | 0.042 | |||
I | 8 | 5 | 3 | |
II | 30 | 18 | 12 | |
III | 74 | 32 | 42 | |
IIII | 2 | 0 | 2 | |
Vessel carcinoma embolus | 0.603 | |||
0 | 25 | 13 | 12 | |
1 | 59 | 27 | 32 | |
Nerve tumor infiltrates | 0.819 | |||
0 | 30 | 14 | 16 | |
1 | 20 | 10 | 10 | |
Expression of Ki67 | 0.124 | |||
< 60% | 44 | 25 | 19 | |
≥ 60% | 58 | 24 | 34 | |
Expression of CD34 | 0.744 | |||
No | 13 | 6 | 7 | |
Yes | 31 | 16 | 15 | |
Expression of EGFR | 0.650 | |||
No | 87 | 43 | 44 | |
Yes | 14 | 6 | 8 | |
Expression of VEGF | 0.779 | |||
No | 41 | 19 | 22 | |
Yes | 61 | 30 | 31 | |
Expression of CDX2 | 0.281 | |||
No | 18 | 11 | 7 | |
Yes | 85 | 40 | 45 | |
Expression of Her2 | 0.954 | |||
No | 75 | 37 | 38 | |
Yes | 26 | 13 | 13 | |
Number of lymphatic metastases | 0.134 | |||
≤ 6 | 58 | 32 | 26 | |
> 6 | 56 | 23 | 33 |
Variables | Group | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|---|
HR | P val. | HR | P val. | |||
CENPO Expression | High (> 1355) | 1 | 1 | |||
Low ( < = 1355) | 1.156(0.836–1.598) | 0.38 | 1.4(0.981–1.998) | 0.064 | ||
Age_at_diagnosis | >=67 | 1 | 1 | |||
< 67 | 0.705(0.509–0.978) | 0.036 | 0.595(0.412–0.861) | 0.006 | ||
Gender | Female | 1 | 1 | |||
Male | 1.311(0.923–1.862) | 0.13 | 1.452(0.997–2.115) | 0.052 | ||
Stage | T1/2 | 1 | 1 | |||
T3/4 | 1.83(1.287–2.603) | 0.001 | 1.096(0.62–1.935) | 0.753 | ||
Pathologic_T | T1/2 | 1 | 1 | |||
T3/4 | 1.653(1.095–2.495) | 0.017 | 1.496(0.894–2.503) | 0.125 | ||
Pathologic_N | N0/1 | 1 | 1 | |||
N2/3 | 1.587(1.142–2.204) | 0.006 | 1.538(0.955–2.478) | 0.077 | ||
Pathologic_M | M0 | 1 | 1 | |||
M1 | 2.186(1.257–3.803) | 0.006 | 2.388(1.265–4.511) | 0.007 |